Appointments

BiOasis Technologies Inc. has appointed Christopher P. Lowe, MBA, as chief financial officer and board advisor. Lowe will report to Mark Day, president and chief executive officer of biOasis and will be responsible for the company’s corporate and financial strategy that includes transactions and fundraising. Lowe has over 15 years of senior management experience as president, chief building officer and chief financial officer of various private and public life sciences, medical technology and technology companies. More recently, Lowe has been a partner at FLG Partners, a leading CFO service and board advisory firm in Silicon Valley. Prior to being a partner at FLG, he served as a strategy, financial and management consultant to several public and private companies. He has also served as a member of the board of directors to both public

and private companies, and has chaired audit and compensation committees. Lowe contributes to companies by assisting them with corporate and financial strategy, successive fundraising, public company advising, Wall Street communications, licensing transactions, mergers and acquisitions. Lowe has successfully raised over $5 million in private and public financings, completed over $1 billion in merger and acquisition transactions, negotiated over $300 million in debt instruments for companies, and has overseen three SOX-404 implementations.

Montreal-based BioAmber Inc. has appointed Richard P. Eno as its new chief executive officer and member of the board. Eno brings over 30 years of related management experience to the table from versity in Quebec City and holds a graduate diploma in clinical pharmacy from the same university. As the medical director for Akcea Therapeutics Canada, Komari will lead the company’s medical affairs function and work directly with the Canadian healthcare community to improve patient care for Canadians suffering with lipid disorders. She will be responsible for the development and implementation of the programs, be the link between Akcea and Canada’s medical community, as well as work with leading healthcare providers involved in the treatment of patients with lipid disorders.

Christopher P. Lowe Richard P. Eno

sectors such as, energy, chemical, biotechnological and material industries. He was a president, CEO, and board member of a publicly traded industrial biotechnology company for over five years. Eno began his career in Chevron’s chemical operations with roles in engineering, manufacturing, and construction operations. Later, he began management consulting where he specialized in addressing critical strategic and operational issues and company leadership in the chemical and energy industries. Additionally, he had a leadership role in biotechnology company, Metabolix, and was a senior partner at a global management consultancy. “The board is pleased to have found an individual with an ideal industry background as well as public company experience to assume leadership of BioAmber. Rick is uniquely qualified to lead BioAmber successfully into the future,” said Ray Land, BioAmber’s chairman of the board.

Prime Minister Justin Trudeau

has named Mona Nemer to be Canada’s new chief science advisor. She is currently vice-president of research at the University of Ottawa, where she oversees research strategies, infrastructure and commercialization; and is also a professor in the faculty of medicine and director of the molecular genetics and cardiac regeneration laboratory. Nemer’s office will have a $2 million budget, and she will report to both Trudeau and minister of science, Kirsty Duncan. Her mandate will include providing scientific advice to government ministers, helping to keep government-funded science accessible to the public, and protecting government scientists from being kept quiet. She will also deliver an annual report to the prime minister and science minister on the state of federal government science.

Akcea Therapeutics Canada appointed Nelly Komari B. Pharm., MSc., as medical director. Bringing almost 20 years of biopharmaceutical experience and knowledge, Komari has an extensive knowledge of the cardiovascular and throm-

bosis systems. Akcea Therapeutics Canada, the Canadian subsidiary of Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc. is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. Prior to joining Akcea, Komari held several strategic positions at Sanofi, including medical advisor, and was a member of Sanofi’s global medical launch team. Most recently, Komari was involved in the Canadian launch of the cholesterol fighting drug, Praluent, a PCSK9 inhibitor. She received her pharmacy degree from Laval Uni-

Nelly Komari

Emerald Health Therapeutics

appointed Chris Wagner as new chief executive officer and a director of EHT. Wagner has spent over 25 years in marketing for pharma-

Chris Wagner

ceutical products and the building of biotechnology companies. Wagner will replace Huang, who will continue to focus on the management and growth of one of the company subsidiary’s. He worked with Eli Lilly for 10 years, mounting to global team leader and working in Europe, North America and Asia. He worked on the global marketing of several notable products, including Prozac, Cialis, and Zyprexa. He went on to become vice-president of business development and global marketing at Aspreva Pharmaceuticals Inc., where he aided in the negotiations of global alliances with Roche and Chugai. Most recently, he served as chairman, president and CEO of Contextual Genomics Inc, a molecular bioinformatics company that has worked with AstraZeneca, Pfizer and Sanofi to develop and commercialize genomic cancer diagnostic products.